Inhibikase Therapeutics, Inc. Current Liabilities
Inhibikase Therapeutics, Inc. (IKT) had Current Liabilities of $10.26 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-11
- 2026-06-30: Liabilities, Current $10.26M.
- 2026-03-31: Liabilities, Current $5.71M.
- 2025-12-31: Liabilities, Current $8.30M.
- 2025-09-30: Liabilities, Current $6.70M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $10.26M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $5.71M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $8.30M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $6.70M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $8.80M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $8.55M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $3.73M 10-K · filed 2026-03-26 |
| 2024-09-30 | $4.91M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $3.70M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $4.23M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $3.44M 10-K · filed 2025-03-27 |
| 2023-09-30 | $2.74M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.73M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $2.66M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $3.70M 10-K · filed 2024-03-27 |
| 2022-09-30 | $3.21M 10-Q · filed 2022-11-14 |
| 2021-12-31 | $4.05M 10-K · filed 2023-03-31 |
| 2021-09-30 | $2.71M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $1.91M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $3.59M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $4.72M 10-K · filed 2022-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |